Low-Resistance Training for Pulmonary Hypertension
(RESIST-PH Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine how low-resistance training can improve the well-being and daily function of people with pulmonary arterial hypertension (PAH). The focus is on whether this exercise can reduce frailty and enhance participants' quality of life. Individuals with stable PAH on consistent treatment might be suitable for this study. All participants will engage in the low-resistance training program. As an unphased trial, this study offers participants the chance to contribute to valuable research that could refine exercise recommendations for PAH patients.
Do I need to stop my current medications for this trial?
The trial does not specify if you need to stop your current medications. However, you must be on stable PAH therapy for at least 3 months before joining.
What prior data suggests that low-resistance training is safe for people with pulmonary arterial hypertension?
Research has shown that exercise, including gentle exercise, is generally safe for people with pulmonary hypertension (PH). Studies have found that exercise can enhance patients' exercise capacity, heart and lung fitness, and overall quality of life.
However, exercise is not entirely without risk. Some studies suggest careful monitoring, especially for those with more severe conditions.
Overall, gentle exercise is typically well-tolerated and can complement medical treatment to improve health in people with pulmonary arterial hypertension (PAH).12345Why are researchers excited about this trial?
Researchers are excited about low-resistance training for pulmonary hypertension because it offers a non-pharmacological approach to managing this condition. Unlike standard treatments, which often rely on medications to relax blood vessels and reduce pressure, low-resistance training focuses on improving cardiovascular health through gentle physical activity. This method could potentially enhance exercise capacity and quality of life for patients without the side effects commonly associated with drugs. Moreover, it empowers patients to take an active role in their own care through a sustainable lifestyle change.
What evidence suggests that low-resistance training might be an effective treatment for pulmonary hypertension?
Studies have shown that low-resistance training can greatly improve exercise ability and quality of life for people with pulmonary hypertension, a condition characterized by high blood pressure in the lungs. This exercise helps the heart and lungs work better together to supply oxygen during physical activity. Research also shows it can boost muscle strength and breathing, making daily tasks easier. This training is safe for these patients and can help blood flow more easily through the lungs. Overall, low-resistance training appears to be a promising way to enhance health and well-being in people with pulmonary arterial hypertension.12367
Who Is on the Research Team?
Nadine Al-Naamani, MD, MS
Principal Investigator
University of Pennsylvania
Are You a Good Fit for This Trial?
This trial is for individuals with pulmonary arterial hypertension (PAH) who are experiencing frailty. The study aims to include those who can safely perform low-resistance exercises and are looking to improve their quality of life.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Baseline in-person visit where quality of life and physical performance are assessed, and low-resistance training exercises are demonstrated
Home Exercise Training
Participants perform low-resistance training exercises at home as instructed
Follow-up
Participants return for a follow-up in-person visit where quality of life and physical performance are reassessed, and exit interviews are conducted
What Are the Treatments Tested in This Trial?
Interventions
- Low-Resistance Training
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Pennsylvania
Lead Sponsor